Roche Holding AG’s (RHHBY - Free Report) Genentech announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq, for the treatment of patients suffering from locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either treatment naive or have disease progression at least 12 months after receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant).
Notably, Roche has underperformed the Zacks classified Large Cap Pharmaceuticals industry in the last 12 months. In fact, the stock lost 8.3% in the last 12 months, compared with a drop of 1.7% for the industry.
Coming back to the latest news, we note that Tecentriq is approved in the U.S. for treating advanced bladder cancer patients. As per the press release, urothelial carcinoma accounts for 90% of all bladder cancers and can be found in the renal pelvis, ureter and urethra.
A decision from the FDA is expected by Apr 30, 2017. We remind investors that the FDA generally grants priority review to medicines that have the potential to provide significant improvements in the safety and effectiveness for the treatment, prevention or diagnosis of a serious disease.
In Oct 2016, Tecentriq became the first and the only anti-PDL1 cancer immunotherapy to be approved by the FDA for the treatment of metastatic non-small cell lung cancer (NSCLC). Label expansion should boost the drug’s sales further.
However, competition is stiff in the immunotherapy space with players like Bristol-Myers Squibb (BMY - Free Report) which boasts a robust portfolio with drugs like Opdivo and Yervoy. Merck’s (MRK - Free Report) Keytruda also poses strong competition with approvals for a varied range of cancers.
Roche currently carries a Zacks Rank #4 (Sell). Roche has been investing significant resources in personalized cancer immunotherapy with more than 20 pipeline candidates. Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space with strong demand for its HER2 franchise drugs. The HER2 franchise includes Herceptin, Perjeta and Kadcyla. Approval of new drugs and therapies is critical for Roche at this juncture as the company has been facing stiff generic competition for some of its drugs like Pegasys, Xeloda and Valcyte. In addition, possibility of stiff competition from biosimilars looms large on some of Roche’s key drugs such as Avastin, Rituxan and Herceptin over the long term. The biosimilar versions of MabThera and Herceptin are expected to enter the market soon.
Key Pick in Sector
Sucmapo Pharmaceuticals (SCMP - Free Report) sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucmapo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.74 for 2017, over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>